Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Nuvasive Inc (NUVA)

Nuvasive Inc (NUVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nuvasive Inc 12101 Airport Way Broomfield CA 80021 USA

P: 800-455-1476

Description:

NuVasive, Inc. is one of the leading global medical device companies in the global spine market, focused on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform includes NuVasive's proprietary NVM5 and NVJJB, and Intra-Operative Monitoring services & support, MaXcess. The spine surgery product line includes products for the thoracolumbar and the cervical spine. The biologic product line used to aid the spinal fusion process or bone healing process include Osteocel Plus and Osteocel Pro allograft, as well as other allograft offerings, FormaGraft and AttraX. It acquired Simplify Medical, Ellipse Technologies, Biotronic NeuroNetwork and SafePassage. NuVasive has included its business under NuVasive Specialized Orthopedics, NuVasive Clinical Services and the NuVasive Clinical Services.

Key Statistics

Overview:

Market Capitalization, $K 2,251,118
Enterprise Value, $K 2,005,028
Shares Outstanding, K 52,061
Annual Sales, $ 1,139 M
Annual Net Income, $ -64,090 K
Last Quarter Sales, $ 310,450 K
Last Quarter Net Income, $ -890 K
60-Month Beta 1.18
% of Insider Shareholders 0.47%
Float, K 51,816
% Float 99.53%
Short Volume Ratio 0.22

Growth:

1-Year Return -29.41%
3-Year Return -32.98%
5-Year Return -24.07%
5-Year Revenue Growth 18.39%
5-Year Earnings Growth 1.20%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.47 on 08/03/22
Next Earnings Date 11/08/22
Earnings Per Share ttm 1.73
EPS Growth vs. Prev Qtr -12.96%
EPS Growth vs. Prev Year -21.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NUVA Ratios

Ratio
Price/Earnings ttm 25.03
Price/Earnings forward 19.41
Price/Earnings to Growth 1.72
Return-on-Equity % 11.12%
Return-on-Assets % 4.20%
Profit Margin % -5.63
Net Margin % 15.43
Debt/Equity 1.09
Price/Sales 1.98
Price/Cash Flow 9.11
Price/Book 2.73
Book Value/Share 15.88
Interest Coverage -1.77
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar